Sugi Predict

Sugi Predict / Targets / STK32A

STK32A

Serine/threonine-protein kinase 32A · Q8WU08 · STK32A on Sugi Atlas →

0 patent compounds predicted against STK32A, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to STK32A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER PHASE2/PHASE3RECRUITING
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
PKC412 and 5-Azacytidine PHASE1/PHASE2COMPLETED
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis PHASE2ACTIVE_NOT_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer PHASE2COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors PHASE1COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Exercise in Type 1 Diabetes Mellitus nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer nanUNKNOWN
Biomarker Analysis of Gastrointestinal Cancer nanUNKNOWN
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a STK32A binder may also engage these)

ProteinNameSimilarity
Q8BGW6 — 1.000 Q8BGW6 →
Q9JJX8 — 1.000 Q9JJX8 →
STK32B Serine/threonine-protein kinase 32B 0.999 landscape →
Q6PFQ0 — 0.995 Q6PFQ0 →
Q12706 — 0.995 Q12706 →
Q5R8M1 — 0.994 Q5R8M1 →
Q91VJ4 — 0.994 Q91VJ4 →
P09215 — 0.993 P09215 →
Q755C4 — 0.993 Q755C4 →
Q62074 — 0.993 Q62074 →
Q02111 — 0.992 Q02111 →
STK38 Serine/threonine-protein kinase 38 0.992 landscape →
O13310 — 0.992 O13310 →
A2VDV2 — 0.992 A2VDV2 →
Q9NBK5 — 0.992 Q9NBK5 →
Q39030 — 0.992 Q39030 →
STK38L Serine/threonine-protein kinase 38-like 0.992 landscape →
Q5R4K9 — 0.992 Q5R4K9 →
PRKCQ Protein kinase C theta type 0.992 landscape →
A8XJQ6 — 0.992 A8XJQ6 →
O19111 — 0.991 O19111 →
RPS6KB1 Ribosomal protein S6 kinase beta-1 0.991 landscape →
Q90XF2 — 0.991 Q90XF2 →
Q64682 — 0.991 Q64682 →
Q7TSE6 — 0.991 Q7TSE6 →
Q6TJY3 — 0.991 Q6TJY3 →
Q8C050 — 0.991 Q8C050 →
PRKCD Protein kinase C delta type 0.991 landscape →
F1M7Y5 — 0.991 F1M7Y5 →
Q8BHI9 — 0.990 Q8BHI9 →